Chengdu Brilliant Biopharmaceutical Co., Ltd.
Has Chengdu Brilliant Biopharmaceutical Co., Ltd. received an FDA warning letter about GLP-1 drugs?
Yes. FDA issued Chengdu Brilliant Biopharmaceutical Co., Ltd. a warning letter naming semaglutide, dated Sep 11, 2025, with the FDA subject line “CGMP/Finished Pharmaceuticals/Adulterated.”
FDA records in this index name Chengdu Brilliant Biopharmaceutical Co., Ltd. on Sep 11, 2025.
- Type named in FDA records
- Not stated
- FDA warning letters
- 1
- Drug recall reports
- 0
- Drugs named
- Semaglutide
- Latest record
- Sep 11, 2025
FDA warning letters
| Later letters FDA lists | Letter | |||
|---|---|---|---|---|
| Sep 11, 2025 | CGMP/Finished Pharmaceuticals/Adulterated | Semaglutide | None listed by FDA as of Nov 15, 2026 | fda.gov |
A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.
FDA’s summary excerpts
- Sep 11, 2025: … the Glucagon-Like Peptide-1 Receptor Agonist (GLP-1) API Semaglutide manufactured at your site. Process validation … Full letter
Drug recalls
No openFDA drug recall reports in this index.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 1 product naming semaglutide under the labeler name “Chengdu Brilliant Biopharmaceutical Co., Ltd.”, matched to this company page by exact name. Marketing categories as FDA gives them: BULK INGREDIENT (1).
| 84524-451 | Not given | Semaglutide | POWDER | Not given | 1 g/g | BULK INGREDIENT | Aug 23, 2024 | None given | Dec 31, 2026 | Unfinished drugs |
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA warning letter, Sep 11, 2025
- FDA warning letters (fda.gov full-text search)
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.